BDX-XL2

BIODESIX ACQUIRES INTEGRATED DIAGNOSTICS
READ THE PRESS RELEASE »

It is estimated that 1.57 million incidental lung nodules are detected each year in the US.

– GOULD 2015, “RECENT TRENDS IN THE IDENTIFICATION OF INCIDENTAL PULMONARY NODULES”

What is the BDX-XL2 test?

  • Blood-based classifier designed to identify low-to-moderate risk patients with a likely benign lung nodule
  • Classifier integrates plasma proteins with clinical risk factors associated with lung cancer
  • Test is being validated as a tool to avoid unnecessary invasive procedures in patients with benign lung nodules

PANOPTIC Study

  • A prospective, multicenter observational trial
  • Evaluated the accuracy of BDX-XL2 at identifying benign lung nodules in patients with a pre-test probability of cancer (pCA) ≤ 50%
READ THE PANOPTIC PUBLICATION  

Get in touch

Contact us